P.H.E. Hilkens

984 total citations
17 papers, 507 citations indexed

About

P.H.E. Hilkens is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, P.H.E. Hilkens has authored 17 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in P.H.E. Hilkens's work include Cancer Treatment and Pharmacology (9 papers), Glioma Diagnosis and Treatment (5 papers) and Multiple Myeloma Research and Treatments (4 papers). P.H.E. Hilkens is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Glioma Diagnosis and Treatment (5 papers) and Multiple Myeloma Research and Treatments (4 papers). P.H.E. Hilkens collaborates with scholars based in Netherlands. P.H.E. Hilkens's co-authors include Martin J. van den Bent, Jaap Verweij, G. Stoter, Wim L.J. van Putten, Ch.J. Vecht, C. J. Vecht, M.E.L. van der Burg, Johan Reimerink, Bart J. M. Vlaminckx and Steven Thijsen and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Annals of Oncology.

In The Last Decade

P.H.E. Hilkens

17 papers receiving 484 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P.H.E. Hilkens Netherlands	11	288	106	88	78	77	17	507
Susanna Kumlien Georén Sweden	15	128 0.4×	107 1.0×	56 0.6×	62 0.8×	86 1.1×	51	838
Kate Murphy Canada	10	313 1.1×	107 1.0×	50 0.6×	132 1.7×	33 0.4×	27	799
Stephen Booth United Kingdom	10	287 1.0×	39 0.4×	21 0.2×	33 0.4×	54 0.7×	19	621
Robert D Sandler United Kingdom	10	106 0.4×	38 0.4×	50 0.6×	23 0.3×	107 1.4×	28	454
Jutte van der Werff ten Bosch Belgium	15	113 0.4×	44 0.4×	14 0.2×	129 1.7×	123 1.6×	57	671
Marc Hoffmann United States	10	209 0.7×	45 0.4×	17 0.2×	32 0.4×	65 0.8×	58	428
Aurora Medina‐Sansón Mexico	13	197 0.7×	110 1.0×	9 0.1×	144 1.8×	79 1.0×	40	665
Nathan Rubin United States	14	92 0.3×	66 0.6×	102 1.2×	39 0.5×	9 0.1×	60	583
D Kamat United States	9	144 0.5×	44 0.4×	9 0.1×	65 0.8×	53 0.7×	17	410
Beate Steiner Germany	11	100 0.3×	58 0.5×	17 0.2×	64 0.8×	217 2.8×	27	449

Countries citing papers authored by P.H.E. Hilkens

Since Specialization

Citations

This map shows the geographic impact of P.H.E. Hilkens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P.H.E. Hilkens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P.H.E. Hilkens more than expected).

Fields of papers citing papers by P.H.E. Hilkens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P.H.E. Hilkens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P.H.E. Hilkens. The network helps show where P.H.E. Hilkens may publish in the future.

Co-authorship network of co-authors of P.H.E. Hilkens

This figure shows the co-authorship network connecting the top 25 collaborators of P.H.E. Hilkens. A scholar is included among the top collaborators of P.H.E. Hilkens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P.H.E. Hilkens. P.H.E. Hilkens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Schaik, Sander M. Van, Paul J.A.M. Brouwers, P.H.E. Hilkens, et al.. (2022). Development of a patient decision aid for discharge planning of hospitalized patients with stroke. BMC Neurology. 22(1). 245–245. 10 indexed citations

Hilkens, P.H.E., et al.. (2022). Increased frequency of CYP2C19 loss‐of‐function alleles in clopidogrel‐treated patients with recurrent cerebral ischemia. British Journal of Clinical Pharmacology. 88(7). 3335–3340. 5 indexed citations

Brok, Melina G.H.E. den, Bob Roozenbeek, Aad van der Lugt, et al.. (2020). Prevalence and risk factors of symptomatic carotid stenosis in patients with recent transient ischaemic attack or ischaemic stroke in the Netherlands. European Stroke Journal. 5(3). 271–277. 10 indexed citations

Thijsen, Steven, Johan Reimerink, P.H.E. Hilkens, et al.. (2020). First autochthonous human West Nile virus infections in the Netherlands, July to August 2020. Eurosurveillance. 25(46). 75 indexed citations

Leeuwen, Nikki van, Esmée Venema, M. Limburg, et al.. (2019). Value-based healthcare in ischemic stroke care: case-mix adjustment models for clinical and patient-reported outcomes. BMC Medical Research Methodology. 19(1). 229–229. 19 indexed citations

Stege, Gerben, Petra J.E. Vos, P. N. Richard Dekhuijzen, et al.. (2012). Manual vs. automated analysis of polysomnographic recordings in patients with chronic obstructive pulmonary disease. Sleep And Breathing. 17(2). 533–539. 3 indexed citations

Hilkens, P.H.E. & A.W. de Weerd. (2009). Non-convulsive status epilepticus as cause for focal neurological deficit. Acta Neurologica Scandinavica. 92(3). 193–197. 5 indexed citations

Bent, Martin J. van den, Wim L.J. van Putten, P.H.E. Hilkens, Ronald de Wit, & M.E.L. van der Burg. (2002). Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. European Journal of Cancer. 38(3). 387–391. 28 indexed citations

Bent, Martin J. van den, et al.. (1998). Lhermitte's sign following chemotherapy with docetaxel. Neurology. 50(2). 563–564. 24 indexed citations

10.

Hilkens, P.H.E., Jaap Verweij, C. J. Vecht, G. Stoter, & Martin J. van den Bent. (1997). Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Annals of Oncology. 8(2). 187–190. 77 indexed citations

11.

Pronk, L., Jan H.M. Schellens, A.S.T. Planting, et al.. (1997). Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 15(3). 1071–1079. 61 indexed citations

12.

Hilkens, P.H.E., et al.. (1997). Chemotherapy-induced peripheral neuropathy.. PubMed. 2(4). 350–61. 65 indexed citations

13.

Hilkens, P.H.E., Jaap Verweij, G. Stoter, et al.. (1996). Peripheral neurotoxicity induced by docetaxel. Neurology. 46(1). 104–108. 87 indexed citations

14.

Hilkens, P.H.E., M.E.L. van der Burg, J. Moll, et al.. (1995). Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. European Journal of Cancer. 31(5). 678–681. 18 indexed citations

15.

Hilkens, P.H.E., M.E.L. van der Burg, J. Moll, et al.. (1995). Effect of an ACTH(4–9) analogue on cisplatin neuropathy of longstanding duration: a phase II study. Clinical Neurology and Neurosurgery. 97(2). 139–141. 3 indexed citations

16.

Markusse, H. M., P.H.E. Hilkens, Martin J. van den Bent, & C. J. Vecht. (1995). Normal pressure hydrocephalus associated with rheumatoid arthritis responding to prednisone.. PubMed. 22(2). 342–3. 6 indexed citations

17.

Hilkens, P.H.E., André Planting, M.E.L. van der Burg, et al.. (1994). Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. European Journal of Neurology. 1(1). 45–50. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact